John Sourbeer
Stock Analyst at UBS
(0.94)
# 3,916
Out of 5,090 analysts
42
Total ratings
42.86%
Success rate
-15.52%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $9.54 | +31.03% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $128.96 | -6.95% | 4 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $280.23 | +26.68% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $47.01 | +6.36% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $185.80 | +29.17% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $22.11 | +6.29% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $27.76 | +62.10% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $2.39 | -16.32% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $548.12 | -12.43% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $48.03 | +112.37% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $17.77 | +181.37% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $125.08 | +2.33% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $9.54
Upside: +31.03%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $128.96
Upside: -6.95%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $280.23
Upside: +26.68%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $47.01
Upside: +6.36%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $185.80
Upside: +29.17%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $22.11
Upside: +6.29%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $27.76
Upside: +62.10%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $2.39
Upside: -16.32%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $548.12
Upside: -12.43%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $48.03
Upside: +112.37%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $17.77
Upside: +181.37%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $125.08
Upside: +2.33%